The Wall Street Journal has caught up with the Genervon controversy, recapping a series of events from the last few days that followed the big social media campaign to gain an instant approval for a new ALS drug based on the results of a 12-patient study. FierceBiotech readers will know already that the data were questioned by Steve Perrin, president and chief scientific officer of the ALS Therapy Development Institute, and that the FDA followed up a day later with an extraordinary challenge to Genervon to publish the data on a drug that the biotech has touted as a major advance for patients.
Northwestern University researchers have developed the first animal model for dementia associated with amyotrophic lateral sclerosis.
A new class of compounds discovered by investigators at the University of Texas Southwestern Medical Center that could treat a range of neurodegenerative disorders has caught the eye of Google's new biotechnology venture Calico.
An antioxidant discovered more than a dozen years ago may be able to treat patients with amyotrophic lateral sclerosis, a devastating neurodegenerative disease that is usually fatal within 5 years of diagnosis that currently has no cure.
A team headed by researchers at the University of Pennsylvania has figured out a way to reduce the toxicity of Lou Gehrig's disease by slowing neuron dysfunction in animal models. The discovery could offer a new way to treat the disease, also known as amyotrophic lateral sclerosis, or ALS.
Eli Lilly and the nonprofit Project A.L.S. are teaming up to boost the pipeline of potential drugs for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig' disease.
An innovative new approach, drawing on the disciplines of both medical science and data science, offers the promise of an unprecedented breakthrough in the search for a cure for amyotrophic lateral sclerosis.
Forced to remedy an error in a study for a potential ALS drug, Cytokinetics has revealed plans to amend the protocol of the midstage trial with expanded enrollment.
Biogen Idec has been unable to shake off Knopp Neurosciences, from which Biogen licensed a compound against Lou Gehrig's disease that fell short in a recent late-stage study.
Biogen Idec ($BIIB) is reaching into its own pocket to make up for a federal tax that hits its gay employees, The Boston Globe reported. Next year the biotech giant is expected to start padding the pay of homosexual staffers who are taxed, unlike their heterosexual coworkers, on health-insurance contributions for their spouses.